Asuragen, Inc. Grants Armored RNA® Technology License to Becton, Dickinson and Company (BDX)
6/19/2012 10:57:46 AM
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that it has granted BD (Becton, Dickinson and Company), a global medical technology company, non-exclusive worldwide rights to incorporate Armored RNA® technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply reagents for BD Diagnostics in Asuragen’s cGMP manufacturing facility. Additional terms were not disclosed.